Ambrisentan
Overview
Ambrisentan is an endothelin receptor antagonist used to treat pulmonary arterial hypertension, improving exercise ability and delaying clinical worsening. It works by selectively blocking the endothelin type-A receptors, leading to vasodilation.
API suppliers (8)
Suppliers of Ambrisentan evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 6 of 8 suppliers.
3 of 8 hold a GMP certificate on record in the EU or UK registers
- MATRIX PHARMACORP PRIVATE LTDIndia1 active DMF
- Zhejiang Huahai Pharmaceutical Co., Ltd.China1 active DMF GMP on record
- Cipla USA, Inc.USA1 active DMF
- MEGAFINE PHARMA P LTDIndia1 active DMF
- JIANGSU JOYGLORY PHARMACEUTICAL CO LTD1 active DMF
- Tianjin Weijie Pharmaceutical Co., Ltd.China1 active DMF
- Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
- WATSON PHARMA PRIVATE LTD GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (16 approved US products), the latest listed US patent on Ambrisentan expires 14 Oct 2031. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Ambrisentan? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.